LifeVantage Corp. (LFVN.OB) Announces Published Review of Protandim’s Ability to Reduce Skin Cancer in Mice
Science-based nutraceutical company LifeVantage Corp. today announced the publication of a peer-reviewed study involving Protandim®, the company’s clinically proven therapy for oxidative stress. Protandim is an indirect antioxidant therapy providing substantial benefits for healthy aging by stimulating the body’s production of its natural antioxidant enzymes. The study, titled "The Chemopreventive Effects of Protandim: Modulation of p53 Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis," demonstrates Protandim’s ability to reduce the incidence and number of skin cancers in mice. The report was published in the scientific journal PLoS ONE, conducted by researchers at Louisiana State University who examined the biochemical mechanisms that…